Skip to content

The Effects of Midazolam, Dexmedetomidine, and Esketamine on Bispectral Index and Raw Electroencephalogram in Patients Under Propofol-Remifentanil Baseline Anesthesia

The Effects of Midazolam, Dexmedetomidine, and Esketamine on Bispectral Index and Raw Electroencephalogram in Patients Under Propofol-Remifentanil Baseline Anesthesia

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07699523
Enrollment
120
Registered
2026-07-13
Start date
2026-06-30
Completion date
2027-12-30
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BIS-EEG, Depth of Anesthesia Monitoring

Keywords

Bispectral Index, Electroencephalography, Midazolam, Dexmedetomidine, Esketamine, Total Intravenous Anesthesia

Brief summary

This prospective, single-center, randomized interventional study aims to investigate the effects of commonly used adjunct anesthetic drugs on the Bispectral Index (BIS) and electroencephalographic (EEG) activity during total intravenous anesthesia. BIS monitoring is widely used to estimate the depth of anesthesia. However, previous studies suggest that certain anesthetic drugs, particularly dexmedetomidine and esketamine, may alter BIS values independently of the patient's actual level of consciousness. As a result, BIS readings may not always accurately reflect anesthetic depth when multiple drugs are administered together. Adult patients undergoing elective laparoscopic cholecystectomy under standardized propofol-remifentanil anesthesia will be randomly assigned to receive one of the following adjunct drugs: midazolam, dexmedetomidine, esketamine, or no additional study drug (control group). Continuous BIS values and raw EEG signals will be recorded throughout the study period. The primary objective is to compare changes in BIS values among different adjunct anesthetic drugs under otherwise similar anesthetic conditions. The study will also explore corresponding EEG characteristics associated with these changes. The findings are expected to improve understanding of drug-related differences in processed EEG monitoring and provide data for future development of more accurate anesthesia depth assessment methods.

Interventions

DRUGMidazolam

Midazolam administered as an adjunct to standardized propofol-remifentanil total intravenous anesthesia according to the study protocol.

DRUGDexmedetomidine

Dexmedetomidine administered as an adjunct to standardized propofol-remifentanil total intravenous anesthesia according to the study protocol.

DRUGEsketamine

Esketamine administered as an adjunct to standardized propofol-remifentanil total intravenous anesthesia according to the study protocol.

DRUGPropofol

Propofol will be administered as part of standardized total intravenous anesthesia in all study groups.

DRUGRemifentanil

Remifentanil will be administered as part of standardized total intravenous anesthesia in all study groups.

Sponsors

China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. ASA physical status I-II; 2. BMI 18-28 kg/m²; 3. Scheduled for elective laparoscopic cholecystectomy, with an expected surgical duration from skin incision to completion of wound closure of ≥45 min; 4. Planned to receive propofol-remifentanil total intravenous anesthesia, with routine intraoperative BIS monitoring and simultaneous acquisition of raw EEG signals; 5. Voluntarily agrees to participate in this study, has signed the informed consent form, and is able to cooperate with the intervention and assessment procedures.

Exclusion criteria

1. A confirmed history of psychiatric or neurological disorders, or use of antipsychotics, antidepressants, benzodiazepines, or other sedative-hypnotic drugs within 4 weeks before surgery; 2. Cognitive impairment identified by Mini-Cog screening; 3. Poorly controlled or untreated hypertension, sinus bradycardia, or severe cardiac conduction block; 4. Acute angle-closure glaucoma; 5. Known allergy to any required anesthetic drug; 6. Difficulty in electrode placement or any condition that may interfere with EEG monitoring.

Design outcomes

Primary

MeasureTime frameDescription
Change in Bispectral Index (BIS) value from the pre-intervention baselineBaseline and 5, 10, 15, 20, 25, 30 minutes after adjunct drug administrationChange in Bispectral Index value from the stable pre-intervention baseline will be compared among the four study groups after administration of the assigned adjunct anesthetic drug under standardized propofol-remifentanil total intravenous anesthesia. The pre-intervention baseline is defined as the stable BIS value immediately before administration of the assigned adjunct anesthetic drug. The Bispectral Index is a dimensionless electroencephalography-derived index ranging from 0 to 100, with lower values indicating deeper hypnotic states.

Secondary

MeasureTime frameDescription
Change in mean arterial pressure from pre-intervention baselineBaseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.Change in mean arterial pressure (MAP) from the stable pre-intervention baseline will be compared among the four study groups after administration of the assigned adjunct anesthetic drug under standardized propofol-remifentanil total intravenous anesthesia.
Change in heart rate from pre-intervention baselineBaseline and 5, 10, 15, 20, 25, and 30 minutes after adjunct drug administration.Change in heart rate (HR) from the stable pre-intervention baseline will be compared among the four study groups after administration of the assigned adjunct anesthetic drug.
Time from discontinuation of anesthetic drugs to airway device removalFrom discontinuation of anesthetic drugs to airway device removal, up to 60 minutes.The time interval from discontinuation of anesthetic drugs to removal of the airway device will be recorded.
Time to Aldrete score of 10 in the post-anesthesia care unitFrom admission to the post-anesthesia care unit to achievement of an Aldrete score of 10, up to 2 hours.The time from admission to the post-anesthesia care unit to achievement of an Aldrete score of 10 will be recorded. The Aldrete score ranges from 0 to 10, with higher scores indicating better post-anesthesia recovery.
Brice questionnaire assessmentBefore discharge from the post-anesthesia care unit, and at 24 and 48 hours after surgery.The Brice questionnaire will be used to assess postoperative recall and awareness-related events.
Postoperative pain scoreAt admission to the post-anesthesia care unit, before discharge from the post-anesthesia care unit, and at 24 and 48 hours after surgery.Postoperative pain intensity will be assessed using the numeric rating scale (NRS).
Postoperative analgesic medication useFrom admission to the post-anesthesia care unit to 48 hours after surgery.Use of postoperative analgesic medications, including opioid and non-opioid analgesics (e.g., NSAIDs), in the post-anesthesia care unit and hospital ward will be recorded and compared among study groups.

Countries

China

Contacts

CONTACTLi
lizhao2001@aliyun.com+86-15811578082

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026